• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Pharmanovia Obtains Sanofi’s Central Nervous System Collection


Deal features 11 brands including Frisium and Gardenal.

3d illustration of human body nerves system. Image Credit: Adobe Stock Images/PIC4U

Image Credit: Adobe Stock Images/PIC4U

Pharmanovia has officially expanded its neurology arsenal with the acquisition of 11 central nervous system (CNS) brands from Sanofi. Focusing on the psycholeptic, anxiolytic, anti-epileptic and anti-psychotic therapy areas, the acquired treatments include Frisium, Sentil, Urbanyl, Urbanil, Urbanol, Urbadan, Noiafren, and Castilium.

"Sanofi’s decision to divest this established CNS portfolio, with leading brands such as Frisium and Gardenal, to Pharmanovia is recognition of our neurology expertise, our capabilities in lifecycle management and reputation of being a trusted divestment partner,” said James Burt, PhD, CEO, Pharmanovia, in a company press release. “We’re excited to use this knowledge and our global platform to ensure these important medicines not only continue to be available to the millions of patients who need them, but - through our lifecycle management - continue to evolve to meet patient needs.”

Reference: Pharmanovia Acquires Global Central Nervous System (CNS) Portfolio from Sanofi. Business Wire. September 18, 2023. Accessed August 19, 2023. https://www.businesswire.com/news/home/20230918003077/en/Pharmanovia-Acquires-Global-Central-Nervous-System-CNS-Portfolio-From-Sanofi

Recent Videos
Related Content